Polycythemia Vera

"Polycythemia Vera" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A myeloproliferative disorder of unknown etiology, characterized by abnormal proliferation of all hematopoietic bone marrow elements and an absolute increase in red cell mass and total blood volume, associated frequently with splenomegaly, leukocytosis, and thrombocythemia. Hematopoiesis is also reactive in extramedullary sites (liver and spleen). In time myelofibrosis occurs.

Descriptor ID	D011087
MeSH Number(s)	C04.588.448.200.500 C15.378.190.250.500 C15.378.190.636.753 C15.378.400.200.500
Concept/Terms	Polycythemia Vera Polycythemia Vera Primary Polycythemia Polycythemia, Primary Polycythemias, Primary Primary Polycythemias Polycythemia Rubra Vera Polycythemia Rubra Veras Vera, Polycythemia Rubra Veras, Polycythemia Rubra Polycythemia Ruba Vera Polycythemia Ruba Veras Ruba Vera, Polycythemia Ruba Veras, Polycythemia Vera, Polycythemia Ruba Veras, Polycythemia Ruba Osler-Vaquez Disease Disease, Osler-Vaquez Osler Vaquez Disease Erythremia Erythremias

Below are MeSH descriptors whose meaning is more general than "Polycythemia Vera".

Diseases [C]
Neoplasms [C04]
Neoplasms by Site [C04.588]
Hematologic Neoplasms [C04.588.448]
Bone Marrow Neoplasms [C04.588.448.200]
Polycythemia Vera [C04.588.448.200.500]
Hemic and Lymphatic Diseases [C15]
Hematologic Diseases [C15.378]
Bone Marrow Diseases [C15.378.190]
Bone Marrow Neoplasms [C15.378.190.250]
Polycythemia Vera [C15.378.190.250.500]
Myeloproliferative Disorders [C15.378.190.636]
Polycythemia Vera [C15.378.190.636.753]
Hematologic Neoplasms [C15.378.400]
Bone Marrow Neoplasms [C15.378.400.200]
Polycythemia Vera [C15.378.400.200.500]

Below are MeSH descriptors whose meaning is related to "Polycythemia Vera".

Below are MeSH descriptors whose meaning is more specific than "Polycythemia Vera".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Polycythemia Vera" by people in this website by year, and whether "Polycythemia Vera" was a major or minor topic of these publications.

Bar chart showing 110 publications over 22 distinct years, with a maximum of 17 publications in 2017

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1999	0	1	1
2002	0	1	1
2003	0	1	1
2004	1	0	1
2005	0	2	2
2006	3	0	3
2007	11	3	14
2008	2	1	3
2009	5	0	5
2010	2	0	2
2011	2	2	4
2012	1	0	1
2013	5	1	6
2014	7	0	7
2015	13	2	15
2016	9	1	10
2017	14	3	17
2018	4	0	4
2019	2	2	4
2020	5	0	5
2021	2	0	2
2022	2	0	2

Below are the most recent publications written about "Polycythemia Vera" by people in Profiles.

Barrios-Ruiz A, Davila-Gonzalez D, Fountain E, Cheng L, Verstovsek S, Rojas-Hernandez CM. Potential limitations of diagnostic standard codes to distinguish polycythemia vera and secondary erythrocytosis. Sci Rep. 2022 03 18; 12(1):4674.

View in: PubMed
Pemmaraju N, Gerds AT, Yu J, Parasuraman S, Shah A, Xi A, Kumar S, Scherber RM, Verstovsek S. Thrombotic events and mortality risk in patients with newly diagnosed polycythemia vera or essential thrombocythemia. Leuk Res. 2022 04; 115:106809.

View in: PubMed
Pasca S, Chifotides HT, Verstovsek S, Bose P. Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN. Int Rev Cell Mol Biol. 2022; 366:83-124.

View in: PubMed
Verstovsek S, Yu J, Scherber RM, Verma S, Dieyi C, Chen CC, Parasuraman S. Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States. Leuk Lymphoma. 2022 03; 63(3):694-702.

View in: PubMed
Kucine N, Bergmann S, Krichevsky S, Jones D, Rytting M, Jain J, Bennett CM, Resar LMS, Mascarenhas J, Verstovsek S, Hoffman R. Use of pegylated interferon in young patients with polycythemia vera and essential thrombocythemia. Pediatr Blood Cancer. 2021 03; 68(3):e28888.

View in: PubMed
Davila-Gonzalez D, Barrios-Ruiz A, Fountain E, Cheng L, Masarova L, Verstovsek S, Rojas-Hernandez CM. Diagnostic Performance of Erythropoietin Levels in Polycythemia Vera: Experience at a Comprehensive Cancer Center. Clin Lymphoma Myeloma Leuk. 2021 04; 21(4):224-229.

View in: PubMed
Chifotides HT, Bose P, Verstovsek S. Givinostat: an emerging treatment for polycythemia vera. Expert Opin Investig Drugs. 2020 Jun; 29(6):525-536.

View in: PubMed
Gangaraju R, Song J, Kim SJ, Tashi T, Reeves BN, Sundar KM, Thiagarajan P, Prchal JT. Thrombotic, inflammatory, and HIF-regulated genes and thrombosis risk in polycythemia vera and essential thrombocythemia. Blood Adv. 2020 03 24; 4(6):1115-1130.

View in: PubMed
Kiladjian JJ, Zachee P, Hino M, Pane F, Masszi T, Harrison CN, Mesa R, Miller CB, Passamonti F, Durrant S, Griesshammer M, Kirito K, Besses C, Moiraghi B, Rumi E, Rosti V, Blau IW, Francillard N, Dong T, Wroclawska M, Vannucchi AM, Verstovsek S. Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study. Lancet Haematol. 2020 Mar; 7(3):e226-e237.

View in: PubMed
Santos FPS, Getta B, Masarova L, Famulare C, Schulman J, Datoguia TS, Puga RD, Alves Paiva RM, Arcila ME, Hamerschlak N, Kantarjian HM, Levine RL, Campregher PV, Rampal RK, Verstovsek S. Prognostic impact of RAS-pathway mutations in patients with myelofibrosis. Leukemia. 2020 03; 34(3):799-810.

View in: PubMed

People

Explore

Similar Concepts

Top Journals